Trial · NCT06392386
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 30
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL) | Up to 12 weeks | |
| Primary | Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd) | Up to 12 weeks | |
| Primary | Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysis | Up to 12 weeks | |
| Primary | Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysis | Up to 12 weeks | |
| Secondary | Incidence of adverse events (AEs) | Up to 14 weeks | |
| Secondary | Severity of adverse events (AEs) | Up to 14 weeks | |
| Secondary | Incidence of serious adverse events (SAEs) | Up to 14 weeks | |
| Secondary | Severity of serious adverse events (SAEs) | Up to 14 weeks | |
| Secondary | Incidence of adverse events of special interest (AESI) | Up to 14 weeks | |
| Secondary | Severity of adverse events of special interest (AESI) | Up to 14 weeks | |
| Secondary | Efgartigimod serum concentrations | Up to 12 weeks | |
| Secondary | Absolute values of total Immunoglobulin G (IgG) from blood samples | Up to 12 weeks | |
| Secondary | Change from baseline values of total Immunoglobulin G (IgG) from blood samples | Up to 12 weeks | |
| Secondary | Percentage change from baseline values of total Immunoglobulin G (IgG) from blood samples | Up to 12 weeks | |
| Secondary | Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples | Up to 12 weeks | |
| Secondary | Change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples | Up to 12 weeks | |
| Secondary | Percentage change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples | Up to 12 weeks | |
| Secondary | Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples | Up to 12 weeks | |
| Secondary | Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples | Up to 12 weeks | |
| Secondary | Incidence of antibodies against rHuPH20 in serum samples | Up to 12 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06392386/registered